BACKGROUND: @entity29 ( @entity29 ) and @entity1744 ( @entity1744 ) are chronic @entity344 of unknown aetiology of increasing incidence and changing disease activity or severity. Approximately 60-80% of @entity29 @entity1 suffer from @entity1744 . Monitoring and treatment goals of @entity29 are to optimise the disease course by prolonging remission periods and preventing or shortening periods of active disease. Constant-care web-monitoring and treatment approaches with active @entity1 involvement have been proven effective in UC, increasing @entity1 ' adherence and improving the disease outcomes.    AIM: To assess the feasibility and efficacy of the novel constant-care eHealth applications in: i) @entity1050 @entity1 treated with infliximab (IFX), ii) UC @entity1 with active disease on @entity2983 , iii) @entity1744 @entity1 and iv) @entity29 @entity1 with @entity1744 on a low FODMAP diet (LFD).    METHODS: New constant-care web applications www.cd.constant-care.dk, www.meza.constant-care.dk and www.ibs.constant-care.dk in @entity29 @entity1 were developed and assessed in this thesis. An integrated inflammatory burden measure of disease activity, consisting of a subjective (clinical indices) and of an objective (faecal calprotectin) part and a treatment guide to drug doses and intervals, was incorporated into the web applications and used by @entity1 . RESULTS: Web-guided IFX treatment in @entity1050 demonstrated @entity1 ' inter- and intra-individual variability in infusion intervals and provided @entity1 with individualised treatment according to their needs. Web-guided treatment with multimatrix @entity2983 was efficacious in a majority of UC @entity1 with mild-to-moderate disease activity. Web-guided @entity1744 -monitoring in @entity29 and in @entity1744 @entity1 on LFD was shown to be a feasible method that actively involved @entity1 in their disease management and had a positive short-term impact on the disease. Moreover, the new constant-care concepts were demonstrated to be safe and to have a positive impact on quality of life and adherence to treatment and helped to reduce the costs.    CONCLUSIONS: The novel constant-care web applications have proven feasible in improving the disease outcomes in @entity1050 @entity1 on IFX, in UC @entity1 on @entity2983 , and in monitoring @entity1744 . These applications are expected to be implemented in the clinical practice of gastroenterology in Denmark in the coming years. Future studies will help to assess whether the natural disease course can be improved in the long-term.

EHealth: self-management in @entity29 and in XXXX using novel constant-care web applications. eHealth by constant-care in @entity29 and @entity1744 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal disorders'] @entity29 :: ('MESH:D015212', 'Disease') :: ['Inflammatory bowel disease', 'IBD'] @entity1050 :: ('MESH:D006223', 'Disease') :: ['CD'] @entity1744 :: ('MESH:D043183', 'Disease') :: ['irritable bowel syndrome', 'IBS'] @entity2983 :: ('MESH:D019804', 'Chemical') :: ['mesalazine']
@entity1744 :: (MESH:D043183,Disease) :: ['irritable bowel syndrome']
